Dr. McKay on Unmet Needs for RCC

Rana R. McKay, MD
Published: Thursday, Feb 22, 2018



Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses unmet needs for patients with renal cell carcinoma (RCC).

McKay says that one of the biggest unmet needs is the management of patients with nonclear cell RCC. This population is comprised of a heterogeneous group of patients with multiple histologies, and is historically excluded from clinical trials. Targeting this rare patient population to improve outcomes is going to be an important step forward, says McKay. There are several trials that are investigating various combinations of immunotherapy, but more work is needed to help improve the management of patients with nonclear cell RCC.

Additionally, due to the unmet need of patients with bone metastases, there is a trial investigating a VEGF inhibitor and radium-223 (Xofigo) in patients with RCC and bone metastases. Data from a phase I pilot study of the combination of radium-223 with a VEGF-targeted therapy were recently released.
 


Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses unmet needs for patients with renal cell carcinoma (RCC).

McKay says that one of the biggest unmet needs is the management of patients with nonclear cell RCC. This population is comprised of a heterogeneous group of patients with multiple histologies, and is historically excluded from clinical trials. Targeting this rare patient population to improve outcomes is going to be an important step forward, says McKay. There are several trials that are investigating various combinations of immunotherapy, but more work is needed to help improve the management of patients with nonclear cell RCC.

Additionally, due to the unmet need of patients with bone metastases, there is a trial investigating a VEGF inhibitor and radium-223 (Xofigo) in patients with RCC and bone metastases. Data from a phase I pilot study of the combination of radium-223 with a VEGF-targeted therapy were recently released.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x